Renal Biomarkers Market by Product Type, Distribution Channel, End User 2024-2032
                     Global Renal Biomarkers 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
Accord ing  to  the la tes t  repor t  by  IMARC Group,  t i t l ed  "Renal  B iomarkers  
Market :  Global  Industry  Trends,  Share ,  S ize ,  Growth ,  Opportuni ty  and 
Forecast  2024-2032,"  the  g loba l  rena l  b iomarkers  marke t  s ize  reached US$ 
1.3  B i l l i on  in  2023.
Report Rena l  b iomarkers  re fer  to  ce l l s ,  p ro te ins ,  l i p ids ,  microRNAs,  genes,  
metabo l i tes ,  or  p ro teomic  pa t te rns  that  dete rmine the g lomeru la r  f i l t ra t ion  
Highlight and ra te  (GFR)  o f  the  k idney.  They are  used to  ident i f y  the pa t ien ts  a t  r i sk  o f  
deve lop ing  k idney  d iseases by  measur ing the i r  b lood  or  u r ine  leve ls .  
Description They a lso  ass is t  in  comput ing  d rug dosage and eva lua t ing  pa thogenic  processes or  pharmaco log ica l  responses to  therapeut ic  in te rven t ions .  Owing 
to  these benef i t s ,  rena l  b iomarkers  f ind  ex tens ive  app l i ca t ions ac ross 
labora tor ies  and  hosp i ta ls  across the g lobe.
Request  for  a  PDF sample of  th is  report :  
ht tps : / /www. imarcgroup.com/ rena l -b iomarkers-market / reques tsample
Report Description
Global  Renal  B iomarkers  Market  T rends:
The  marke t  i s  p r imar i l y  d r i ven  by  the  g row ing  p reva lence  o f  ch ron i c  k idney  d iseases  (CKD)  am ong ind iv idua ls  ac ross  
the  g lobe .  I n  add i t i on ,  t he  inc reas ing  u t i l i za t ion  o f  nove l  s ing le  b iomarke rs  and process -spec i f i c  b i omarker  pane ls  to  
eva lua te  response  to  t he  t r ea tmen t  o f  g lomeru lopa th ies ,  acu t e  k i dney  in ju r y  (AK I ) ,  and  au tosomal  dom inan t  po lycys t i c  
k idney  d isease (ADPKD)  i s  pos i t i ve ly  in f l uenc ing  t he  m arke t  g rowt h .  Bes ides  th is ,  r ena l  b iomarkers  a re  w ide ly  u t i l i zed  
in  labo ra t o r ies  t o  assess  the  sa f e t y  and  e f f i c i ency  o f  new d rugs  in  p rec l in i ca l  and  c l in i ca l  t r i a l s .  
Th is ,  coup led  w i th  the  deve lopmen t  o f  genomics ,  ep igenet i cs ,  t ransc r ip tom ics ,  p ro teomics ,  and  met abo lom ics ,  i s  
c rea t i ng  a  pos i t i ve  marke t  ou t look  ac ross  t he  g lobe .  Fu r the rmore ,  t he  inc reas ing  gove rnmen t  i nves t men ts  in  
deve lop ing  hea l thcare  in f r as t ruc tu re ,  t he  r i s i ng  ge r ia t r i c  popu la t ion ,  and  ex tens ive  research  and  deve lopmen t  (R&D)  
ac t i v i t i es  and  t r ia l s  f o r  CKD are  some o f  t he  o t he r  f ac t o rs  p rope l l i ng  t he  marke t  g rowth .
Look ing  forward ,  IMARC Group  expects  the  market  va lue  to  reach  US$  2 .5  B i l l i on  by  2032,  exh i b i t i ng  a  CAGR 
of  6 .9% dur i ng  the  forecast  per i od  (2024-2032) .
V i ew Report  TOC,  F igures and  Tab les :  h t tps: / / www. i marcgroup .com/rena l -b i omarkers -market
Breakup by Biomarker Type:
• Funct ional  Biomarker
o Serum Creatin ine
o Serum Cystat in  C
o Urine Albumin
• Up-regulated Protein
o Neutrophi l  Gelat inase-Associated 
Report Lipocal in (NGAL)
o Kidney In jury Molecule-1
Segmentation o INTERLEUKIN-18
• Others
 
Breakup by Diagnostic Technique:
• Enzyme- l inked Immunosorbent  Assay (ELISA)
• Part ic le -enhanced Turb idimetr ic  Immunoassay 
(PETIA)
• Colorimetr ic  Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry 
(LC-MS)
Breakup by End User:
• Hospital
• Diagnost ic  Laboratory
Report • Others
Segmentation
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Lat in America
• Middle East and Afr ica
• Abbott Laboratories
• Beckman Coulter Inc.  (Danaher 
Corporation)
• bioMérieux SA
Competitive • BioPorto A/S
Landscape • Bio-Rad Laboratories Inc.
with Key • Enzo Biochem Inc.
• F. Hoff mann-La Roche AG
Players • PerkinElmer Inc.
• Randox Laboratories Ltd.
• Siemens AG
• Thermo Fisher Scient ifi c Inc.
What was the size of the global renal biomarkers 
market in 2023?
What is the expected growth rate of the global renal 
biomarkers market during 2024-2032?
What has been the impact of COVID-19 on the global 
renal biomarkers market?
Key 
What are the key factors driving the global renal 
Questions biomarkers market?
Answered in What is the breakup of the global renal biomarkers market based on the biomarker type?
the Report What is the breakup of the global renal biomarkers market based on the diagnostic technique?
What is the breakup of the global renal biomarkers 
market based on end user?
What are the key regions in the global renal biomarkers 
market?
Who are the key players/companies in the global renal 
biomarkers market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  R e n a l  B i o m a r k e r s  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  B i o m a r k e r  T y p e
    6 . 1     F u n c t i o n a l  B i o m a r k e r
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  K e y  S e g m e n t s
           6 . 1 . 2 . 1  S e r u m  C r e a t i n i n e
           6 . 1 . 2 . 2  S e r u m  C y s t a t i n  C
           6 . 1 . 2 . 3  U r i n e  A l b u m i n
        6 . 1 . 3  M a r k e t  F o r e c a s t
    6 . 2     U p - r e g u l a t e d  P r o t e i n
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  K e y  S e g m e n t s
       
           6 . 2 . 2 . 1  N e u t r o p h i l  G e l a t i n a s e - A s s o c i a t e d  L i p o c a l i n  ( N G A L )
           6 . 2 . 2 . 2  K i d n e y  I n j u r y  M o l e c u l e - 1
           6 . 2 . 2 . 3  I N T E R L E U K I N - 1 8
        6 . 2 . 3  M a r k e t  F o r e c a s t
    6 . 3     O t h e r s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D i a g n o s t i c  T e c h n i q u e
    7 . 1     E n z y m e - l i n k e d  I m m u n o s o r b e n t  A s s a y  ( E L I S A )
        7 . 1 . 1  M a r k e t  T r e n d s
Table of         7 . 1 . 2  M a r k e t  F o r e c a s t    7 . 2     P a r t i c l e - e n h a n c e d  T u r b i d i m e t r i c  I m m u n o a s s a y  ( P E T I A )
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
Contents     7 . 3     C o l o r i m e t r i c  A s s a y
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     C h e m i l u m i n e s c e n t  I m m u n o a s s a y  ( C L I A )
        7 . 4 . 1  M a r k e t  T r e n d s
        7 . 4 . 2  M a r k e t  F o r e c a s t
    7 . 5     L i q u i d  C h r o m a t o g r a p h y  M a s s  S p e c t r o m e t r y  ( L C - M S )
        7 . 5 . 1  M a r k e t  T r e n d s
        7 . 5 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  E n d  U s e r
    8 . 1     H o s p i t a l
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m / rena l -b i o m arke r s -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: